Internal Medicine, Hematology & Oncology · New Haven, CT
NPI
1265669600
Since 2009
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
20 York St, Tompkins, 209
New Haven, CT, 06510
Phone (203) 688-9503
Groups this clinician bills Medicare through
Medicare paid, 2024
$18K
195 services
Medicare patients, 2024
102
Average age 74
Drug cost, 2024
$2.1M
371 prescriptions
Company payments, 2025
$1,664
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Melinda L Yushak was code 99215 (office e&m - established), 86 times for 47 patients. In total Melinda L Yushak billed 195 services in 6 codes, and Medicare paid $18K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-08-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 86 | 47 | $113.43 | $9,755 |
| 99214 Office E&M - Established | Office | 75 | 56 | $74.56 | $5,592 |
| 99213 Office E&M - Established | Office | 19 | 18 | $54.53 | $1,036 |
By year: 2022 $29K for 318 services; 2023 $23K for 260 services; 2024 $18K for 195 services.
Medicare prescription drug claims, 2024
In 2024, the drug Melinda L Yushak prescribed most often to Medicare patients was Braftovi (Encorafenib), with 50 prescriptions and refills. In total Melinda L Yushak wrote 371 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Braftovi Encorafenib | 50 | 50 | Under 11 | $733K |
| Mektovi Binimetinib | 48 | 48 | Under 11 | $517K |
| Mekinist Trametinib Dimethyl Sulfoxide | 22 | 22 | Under 11 | $314K |
| Ondansetron Hcl Generic | 22 | 22 | 14 | $760 |
| Gabapentin Generic | 20 | 20 | Under 11 | $53.99 |
| Tafinlar Dabrafenib Mesylate | 19 | 19 | Under 11 | $230K |
| Prochlorperazine Maleate Generic | 16 | 16 | 11 | $172 |
| Erivedge Vismodegib | 16 | 16 | Under 11 | $193K |
| Eliquis Apixaban | 15 | 18 | Under 11 | $10K |
| Oxycodone Hcl Generic | 14 | 14 | Under 11 | $113 |
Brand drugs: 189 claims; generic drugs: - claims; opioid claims: 20.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Melinda L Yushak $1,664 ($104 in general payments such as food, travel and fees and $1,560 for research) from 4 companies. The largest payer was Regeneron Pharmaceuticals, Inc. with $1,560.
| Company | Payments | Amount |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. REGN | 7 | $1,560 |
| Aadi Bioscience, Inc. | 1 | $104 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.